Great science means sharing knowledge and resources to work faster and achieve more.
Academic collaborations are a rich source of creativity and scientific talent. Pooling resources and expertise can help the UK life sciences community to find and develop more new medicines and vaccines than by working in isolation. It’s what we call our “R&D ecosystem”.
Today, Pfizer contributes to more than 300 research collaborations and strategic alliances across the UK. Through these partnerships, we work with scientists, academics and clinicians to deliver world leading scientific research.
Through the Rare Disease Consortium (RDC), we are partnering with the Global Medical Excellence Cluster (GMEC) group of six leading UK universities, to identify and work together to develop new medicines for rare diseases, accelerating the discovery of new treatments for rare and devastating conditions.
But it’s not just rare conditions where such collaborations can be beneficial. Lung cancer is the second most common cancer diagnosed in the UK after breast cancer and is the most common cancer in the world, with an estimated 1.61 million new cases diagnosed every year. Responding to this, we have embarked on a partnership with Cancer Research UK and AstraZeneca to create a pioneering clinical trial for patients with advanced lung cancer. The Stratified Medicine Programme (SMP) aims to make targeted treatments available for people with cancer in the UK.
In addition, scientists at Neusentis in Cambridge together with University College London and Moorfields Eye Hospital are working on a stem-cell based therapy for age related macular degeneration, a condition that leads to loss of vision.
Our partnerships in the UK extend far beyond the initial discovery of a new molecule. Our INSPIRE partnerships with the NHS in Newcastle, Scotland and Bath mean that these organisations are part of Pfizer’s international network of preferred sites for clinical research, helping to bring innovative medicines to patients in the UK and around the world.
At last count, we had 75 ongoing clinical trials at 331 sites across the UK involving over 2,400 patients, enabling people in the UK to access the latest innovations in medical science.